Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q1 2023 · 10-Q
Revenue$13.00M$13.00M−5.3% vs Q1 2022 Net Income-$6.40M-$6.40MN/M vs Q1 2022 EPS Diluted-$0.37-$0.37N/M vs Q1 2022 Gross Profit$7,433,000−8.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flow-$86,000N/M Free Cash Flowderived-$114,580N/M Margins · derivedGross margin57.2%−1.8 pt vs Q1 2022
Operating margin-54.3%−26.9 pt vs Q1 2022
Net margin-49.2%−21.8 pt vs Q1 2022
ended Mar 31, 2023 · filed May 12, 2023 · 42 d after period end